I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients..:
Mohammad Shehab
;
Fatema Alrashed
;
Ahmad Alfadhli
...
https://www.frontiersin.org/articles/10.3389/fmed.2022.933996/full. , 2022
Link:
https://doi.org/10.3389/fmed.2022.933996
RT Journal T1
Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:3a274ee2cdc04b8daf41bc28c2d17fcd&Exemplar=1&LAN=DE A1 Mohammad Shehab A1 Fatema Alrashed A1 Ahmad Alfadhli A1 Abdulwahab Alsayegh A1 Usama Aldallal A1 Mariam Alsayegh A1 Preethi Cherian A1 Irina Alkhair A1 Thangavel Alphonse Thanaraj A1 Arshad Channanath A1 Ali A. Dashti A1 Anwar Albanaw A1 Hamad Ali A1 Mohamed Abu-Farha A1 Jehad Abubaker A1 Fahd Al-Mulla PB Frontiers Media S.A. YR 2022 K1 IBD K1 vaccine K1 infliximab K1 COVID-19 K1 immunogenicity K1 booster K1 Medicine (General) K1 R5-920 JF https://www.frontiersin.org/articles/10.3389/fmed.2022.933996/full LK http://dx.doi.org/https://doi.org/10.3389/fmed.2022.933996 DO https://doi.org/10.3389/fmed.2022.933996 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)